LAGUNA NIGUEL, Calif.--(BUSINESS WIRE)--Aeolus Pharmaceuticals, Inc. (OTCBB: AOLS) announced today that it has initiated a follow-on Phase I open label compassionate use multiple dose study of AEOL 10150 in a patient diagnosed with progressive and debilitating amyotrophic lateral sclerosis, also referred to as ALS or Lou Gehrig’s disease. The study is being conducted at UCLA by Martina Wiedau-Pazos, M.D., and is designed to evaluate the safety and efficacy of AEOL 10150 in an ALS patient over an extended period of time. The patient will receive a subcutaneous injection of 75mg of AEOL 10150 two times each day for up to 24 weeks. Efficacy and safety data will be monitored in real-time for the duration of the study. The primary objective of this study is to assess the clinical efficacy of AEOL 10150 with respect to the patient’s baseline assessment of functional status. Secondary objectives include the assessments of muscle strength, respiratory function, quality of life and safety.
